Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals

Abstract

The relatively nonrestrictive inclusion/exclusion criteria in the parent ZOE studies resulted in a range of participants that included frail and pre-frail older adults. RZV significantly reduced the risk of herpes zoster across all frailty subgroups.